Suarez-Almazor, MariaPundole, XerxesAbdel-Wahab, NohaJohnson, DouglasGupta, DiptiGlezerman, IlyaCooksley, TimAnderson, RonaldBlidner, Ada GabrielaChoi, JenniferDougan, MichaelGinex, PamelaGirotra, MonicaShannon, Vickie R.Rapoport, Bernardo Leon2020-10-262020-12Suarez-Almazor, M.E., Pundole, X., Abdel-Wahab, N. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care in Cancer 28, 6159–6173 (2020). https://doi.org/10.1007/s00520-020-05710-8.0941-4355 (print)1433-7339 (online)10.1007/s00520-020-05710-8http://hdl.handle.net/2263/76607Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.en© Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520.ArthralgiaImmune checkpoint inhibitor (ICI)ArthritisCardiomyopathyCorticosteroidsMyocarditisMyositisImmunomodulation agentsOther immunosuppressive agentsPolymyalgiaPostprint Article